These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23207933)

  • 1. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
    Herfarth H
    Dig Dis; 2012; 30 Suppl 2():55-9. PubMed ID: 23207933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will a 5-ASA a day keep the cancer (and dysplasia) away?
    Rubin DT; Lashner BA
    Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question.
    Margagnoni G; Pagnini C; Menasci F; Festa S; Delle Fave G
    Curr Clin Pharmacol; 2014 Feb; 9(1):84-90. PubMed ID: 24218994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
    Allgayer H; Kruis W
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):521; author reply 521. PubMed ID: 16616360
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Colorectal cancer in inflammatory bowel disease].
    Henriksen M; Moum B
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of colorectal cancer: feasibility in everyday practice?
    Herszényi L; Farinati F; Miheller P; Tulassay Z
    Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
    MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
    [No Abstract]   [Full Text] [Related]  

  • 11. [5-aminosalicylic acid and cancer prophylaxis?].
    Thomsen OO
    Ugeskr Laeger; 2006 May; 168(21):2047. PubMed ID: 16768920
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
    Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A
    Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
    Fallingborg JF
    Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven.
    Terdiman JP
    Am J Gastroenterol; 2011 Apr; 106(4):737-40. PubMed ID: 21468069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.
    Rubenstein JH; Waljee AK; Jeter JM; Velayos FS; Ladabaum U; Higgins PD
    Am J Gastroenterol; 2009 Sep; 104(9):2222-32. PubMed ID: 19491824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
    Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway.
    Munding J; Ziebarth W; Pox CP; Ladigan S; Reiser M; Hüppe D; Brand L; Schmiegel W; Tannapfel A; Reinacher-Schick AC
    Carcinogenesis; 2012 Mar; 33(3):637-43. PubMed ID: 22198215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
    Velayos FS; Terdiman JP; Walsh JM
    Am J Gastroenterol; 2005 Jun; 100(6):1345-53. PubMed ID: 15929768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aminosalicylates in the treatment of ulcerative colitis.
    Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
    Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.